Abstract: The invention relates to pharmaceutical formulation in form of a pharmaceutical formulation comprising GDC-0077 (INAVOLISIB) or a salt thereof, the formulation having a colored coating.

Abstract: A device configured to guide creation of an incision in a sclera of an eye including an elongate handle and a footplate having a plurality of struts defining a central opening extending between an upper surface and a lower surface of the footplate. A first strut of the plurality of struts has a proximal-facing blade guide surface that is straight and extends between two lateral struts of the plurality of struts. A second strut of the plurality of struts has a proximal-facing limbal guide surface that is curved. The blade guide surface is separated a distance from the limbal guide surface to identify a target location for creating an incision relative to a limbus of the eye. The blade guide surface has a length between the two lateral struts that limits a length of the incision that can be created using a cutting blade inserted through the central opening.

Abstract: Provided are anti-CD8 antibodies that bind human CD8 and do not stimulate or inhibit the activation of CD8+ T cells. Also provided are nucleic acids encoding such anti-CD8 antibodies, vectors comprising such nucleic acids, host cells comprising same, and methods of making such anti-CD8 antibodies. Also provided are anti-CD8 antibodies conjugated to a detectable label. Provided are methods of using such anti-CD8 antibodies to detect CD8+ T cells in a subject, monitor disease progress in a subject having cancer, and monitor treatment progress in a subject having cancer.

Abstract: The invention provides isoform-selective anti-TGF? antibodies and methods of using the same. In particular, isoform-selective anti-TGF?2, anti-TGF?3, and anti-TGF?2/3 monoclonal antibodies are provided, e.g., for the treatment of fibrosis and other TGF?-related disorders.

Abstract: Provided herein are methods of synthesizing quinazoline compounds comprising at least one atropisomeric center.

Abstract: The present disclosure provides methods and kits for treating or preventing an allergic reaction to a food allergen consumed by a human subject with one or more food allergies. In particular, the present disclosure provides prophylactic therapies comprising administration of an anti-IgE antibody at a specific dose to a human subject who is allergic to one or more food allergens.

Abstract: Provided herein are methods of identifying an antigen binding polypeptide variant (e.g., an antibody variant, an antigen-binding fragment thereof, or a variant of an antibody-based construct) having reduced viscosity relative to a parental antigen binding polypeptide (e.g., an antibody, an antigen-binding fragment thereof, or an antibody construct). Also provided are antigen binding polypeptide variants produced by the methods. Further provided are related libraries and methods of screening such libraries. Also provided are methods of identifying one or more amino acids in an antibody, an antigen binding fragment of an antibody, or an antibody construct that affect the viscosity of the antibody, the antigen binding fragment, or the antibody construct. Also provided are exemplary antibody variable domains with reduced viscosity.

Abstract: Provided herein are methods for assessing splice-switching ASOs using a reporter to detect splicing of a cryptic sequence located in the reporter pre-mRNA.

Abstract: The subject matter described herein is directed to methods of preparing compounds of general Formula I: or a salt or solvate thereof.

Abstract: An apparatus includes a body, an outer cannula, and an inner cannula slidably disposed in the outer cannula. The inner cannula includes an open proximal end, an open distal end configured to pierce a retina, and a lumen for delivering first and second fluids into a subretinal region of the eye. The apparatus also includes a first supply conduit configured to supply the first fluid to the lumen, and including a first distal conduit end fixedly secured relative to the inner cannula such that the first distal conduit end is configured to translate longitudinally together with the inner cannula. The apparatus also includes a second supply conduit configured to supply the second fluid to the lumen, and including a second distal conduit end fixedly secured relative to the inner cannula such that the second distal conduit end is configured to translate longitudinally together with the inner cannula.

Abstract: Provided herein are salts and solid forms of 1-((S)-4-((R)-7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)quinazolin-4-yl)-3-methylpiperazin-1-yl)prop-2-en-1-one, including adipate, fumarate, ethylenesulphonate, besylate, and mesylate salts thereof.

Abstract: A composition comprising a main species HER2 antibody that binds to domain II of HER2and acidic variants thereof is described. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed.

Abstract: The present disclosure relates to guide RNAs that have been modified to improve performance and stability. In certain embodiments, a guide RNA of the present disclosure includes one or more modifications at its 5? terminus and/or one or more modifications at its 3? terminus.

Abstract: A method and System for identifying chemical compounds based on Raman spectroscopic measurements and in-silico simulated Raman spectra are disclosed. In various embodiments, Raman barcodes of an unknown chemical compound may be generated from Raman spectra obtained by performing Raman spectroscopic measurements on the unknown chemical compound. The Raman barcodes may then be compared with a library of reference in-silico simulated Raman barcodes of known chemical compounds and the identity of the unknown chemical compound may be determined based on the comparison.

Abstract: The invention provides a compound represented by represented by the following structural formula: or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.

Abstract: The invention provides methods for treating or delaying progression of lupus nephritis in an individual that has lupus. In some embodiments, the methods comprise administering to the individual an effective amount of a type II anti-CD20 antibody. The invention also provides methods for treating or delaying progression of rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) in an individual. In some embodiments, the methods comprise administering an effective amount of an anti-CD20 antibody.

Abstract: The invention provides anti-HER2 antibodies and immunoconjugates and methods of using the same.

Abstract: Provided herein are combination therapies comprising a KRasG12C inhibitor (e.g. Compound 1) and an EGFR-inhibitor and methods of using such combination therapies.